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Background: The causal association between persistent human papillomavirus (HPV) infection and cervical cancer
has been established, but the mechanisms that favor HPV persistence in cervical cells are still unknown. The
diminished capability of the immune system to control and resolve HPV infection is one of several hypotheses. The
tolerogenic protein HLA-G has shown aberrant expression in a variety of cancers, which has been suggested as a
mechanism for tumor escape from immunosurveillance. In the present study we evaluate the role of epigenetic
modification (promoter de-methylation) of the HLA-G gene on susceptibility to HPV infection and development of
high-grade cervical lesions.
Methods: A case–control study was carried out in Curitiba, Brazil, between February and June 2010. A total of 789
women aged 15–47 years were recruited: 510 controls with normal cervical cytology, and 279 cases with
histologically confirmed cervical intraepithelial neoplasia grade 2 (CIN2, N = 150) or grade 3 (CIN3, N = 129). All
women were administered a questionnaire by interview, which collected information on demographic and lifestyle
factors, and a cervical sample was collected. HPV DNA detection was performed by GP5+/GP6+ primer-mediated
PCR. HPV-positive samples were genotyped by multiplex PCR. A pilot analysis of HLA-G promoter methylation was
carried out in a subset of the study population (96 cases and 76 controls) by pyrosequencing. HLA-G methylation
and HPV infection status of cases and controls were compared, and confounding factors were computed by t
Student and non-parametric Wilcoxon tests. Comparison of HLA-G methylation between cases and controls was
assessed by the Bonferroni correction. The association of HLA-G methylation with CIN2/3 was evaluated by logistic
regression.
Results: HPV prevalence was 19.6% in controls and 94.3% in CIN2/3 cases. HPV16, 31, 33, 35 and 18 were the most
prevalent types. Methylation analysis of seven CpGs in the HLA-G promoter did not reveal any spontaneous
de-methylation events in CIN2/3 cases (mean proportion of methylation: 75.8%) with respect to controls (mean
73.7%; odds ratio 1.01, 95% confidence interval 0.96, 1.07).
Conclusions: This study did not support the hypothesis that spontaneous de-methylation events in the HLA-G
promoter play a primary role in promoting escape from immunosurveillance in the development of precancerous
cervical lesions.
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Cervical cancer is the third most common cancer and
the fourth cause of cancer mortality in women world-
wide [1]. Screening programs in industrialized countries
have drastically reduced the incidence and mortality of
cervical cancer, and research in the last decades has
greatly improved our capability to detect the etiologic
viral component of the disease, human papillomavirus
(HPV), and contributed to a decrease in rates of pro-
gression to cervical cancer.
Nevertheless, cervical cancer remains a public health
issue. Several unresolved aspects of the natural history
of the disease also remain. Among these is the mechan-
ism behind the development of cervical cancer. Indeed,
only a small proportion of women infected with HPV
ever develop cervical cancer; in most women the infec-
tion regresses spontaneously. While the causal associ-
ation between persistence of HPV infection and risk of
developing cervical lesions is recognized [2], the events
that promote or prevent this persistence in cervical cells
has not yet been identified. Several hypotheses exist, one
of which is the capability of the immune system to con-
trol and resolve HPV infection. One recently considered
hypothesis focuses on human leucocyte antigen-G
(HLA-G), a tolerogenic protein involved in the control
of immune response, due to its reported aberrant ex-
pression in a wide variety of cancer cells [3-6]. HLA-G is
a non-classical gene of the major hystocompatibility
complex that codes for a protein involved in immuno-
suppressive mechanisms. HLA-G inhibits cell-mediated
immunity through interaction with receptors expressed
on lymphoid, myeloid and natural killer cells [7,8]. It
plays a primary role in immune tolerance, and has been
widely described in fetal-maternal tolerance [9]. The
HLA-G protein is physiologically present in fetal [10]
and immature (thymus [11]) cells, and in a small num-
ber of adult tissues [5,11-13], but it is not commonly
expressed in mature normal cells. HLA-G re-expression
has been suggested as a mechanism of viral [14] and
tumor [3-6] escape from immunosurveillance. Recent
evidence [15] showed that HLA-G expression increased
with grade of precancerous cervical lesions, with the
highest expression found in cervical cancer. Since pro-
moter methylation has been described as one of the cru-
cial mechanisms that regulate gene expression [16],
occurrence of spontaneous de-methylation events in the
HLA-G promoter was postulated to explain the re-
expression of this protein in adult cells. De-methylation
events have been reported in the HLA-G promoter of
ovarian tumor cells compared to normal ovarian epithe-
lial cells [17].
The present study aimed to investigate the association
of HPV infection and development of cervical intrae-
pithelial neoplasia grades 2 (CIN2) and 3 (CIN3) withHLA-G promoter methylation in a Brazilian population.
Association with the characteristics of the study popula-
tion was also evaluated.
Materials and Methods
Study population and sample collection
A case–control study was set up in the framework of the
collaboration among the Unit of Cancer Epidemiology
in Turin, Italy; the Laboratory of Immunogenetics
and Hystocompatibility (LIGH) in Curitiba, Brazil; the
Department of Gynecology and Obstetrics, at the Federal
University of Paraná, Infectious Diseases in Gynecology
and Obstetrics Sector; and the Department of Cervical
Pathology, Hospital Erasto Gaertner, in Curitiba, Brazil.
The study was approved by the Ethical Committee for
Clinical Research of the Hospital Erasto Gaertner (proto-
col CEP: 81520–060, P.P No 1943). All participating
women were informed about the study purpose and
signed an informed consent form.
Women were recruited in Curitiba, where the preva-
lence of HPV infection and cervical lesions has been
reported to be higher than in Turin [18-20]. Under the
supervision of the LIGH, women aged 15 to 47 years
were recruited: local gynecologists working at three
reference centers for cervical cancer screening collabo-
rated to enroll women. Some women were also recruited
through awareness campaigns for adhesion to cervical
screening. Women over 47 years of age were not
included to avoid atrophy or dysplasia associated with
menopause, although the suggested impact of meno-
pausal hormonal status on cervical dysplasia due to a
weakened immune response, specifically in HPV-positive
menopausal women, has not been properly documented.
A total of 789 women were recruited: 510 had normal
cervical cytology and were classified as controls; 279 had
histologically confirmed CIN2 (N = 150) or CIN3 (N =
129) after loop electrosurgical excision procedure or
cold knife conization, and were classified as CIN2/3
cases. A cervical sample was collected from all study
women. Cervical cell samples were collected from con-
trols at collection for cytology using the cytobrush pro-
vided in the collection kit (Digene sample collection kit,
Qiagen, Hilden, Germany), which was then placed into a
tube containing sample transport medium (STM, Qiagen).
A cervical sample was analogously collected in STM from
CIN2/3 cases at loop electrosurgical excision procedure or
cold-knife conization.
Study women were administered a questionnaire by
interview, which collected information on demographic,
sexual and lifestyle factors, including age, education
level, ethnic group, age at first sexual intercourse, life-
time number of sexual partners, number of full-term
pregnancies, smoking status and number of cigarettes
smoked per day. Study women were classified into four
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Euro-Descendent, Afro-Descendent, Brazilian Mixed and
Asian. There is a general consensus as to the definition of a
person of Brazilian Mixed ethnicity in the Genetic Depart-
ment of the Federal University of Paranà in Curitiba, and
following that consensus, all study women with a multi-
racial origin, i.e., a miscegenation of Euro-Descendent
(mostly), Afro-Descendent, Amerindian and East Asian,
were classified as Brazilian Mixed [21]. Women were
assigned to the corresponding ethnic group following inter-
view at recruitment.
DNA extraction
Genomic DNA was extracted from cervical cell samples
using the commercial purification system QIAmp DNA
Mini Kit (Qiagen) according to the manufacturer’s instruc-
tions. The final elution in 100 μl of the provided elution
buffer was repeated twice to increase the DNA yield. The
DNA concentration was evaluated by a Nanodrop spectro-
photometer (Thermo Scientific, Wilmington, DE, USA).
DNA adequacy was checked by amplification of a β-globin
housekeeping gene sequence of 268bp, as previously
described [22]. After gel electrophoresis onto a 2% agarose
gel stained with ethidium bromide, amplicons were visua-
lized by ultraviolet trans-illumination. The amplicon of the
β-globin gene fragment was detected in all the study sam-
ples. Purified DNA was stored at −80°C.
HPV detection
HPV detection was performed in Turin, Italy, on the
genomic DNA extracted from cervical samples by con-
sensus primer GP5+/6 + −mediated PCR [23], which
allows to detect a broad variety of HPV types. PCR reac-
tion was performed in a total volume of 25 μl containing
buffer (KCl) 50 mM, Tris-HC1 10 mM pH 8.3, dNTP
200 μM, MgCl2 3.5 mM, Taq polymerase 1U, GP5+/6+
50 pmol and DNA 5 μl. The following amplification pro-
file was used: 94°C for 9 min, followed by 40 cycles of
denaturation at 94°C for 20s, annealing at 38°C for 30s,
extension at 71°C for 80 s. A final extension of 4 min at
71°C was performed.
HPV genotyping
HPV-positive samples were genotyped by multiplex PCR,
in order to detect the seven oncogenic HPV types that are
prevalent, and more associated with cervical cancer in Bra-
zil [24]: HPV16, 18, 31, 33, 35, 45 and 52. Multiplex PCR
was performed as previously described [25], with the excep-
tion of HPV16, for which a different primer set was used
[26]. Briefly, the PCR mix was carried out in a final volume
of 25 μl containing buffer (KCl) 1X, MgCl2 2 mM, dNTPs
200 μM, 0.4 μM both primers, Taq polymerase 2.5U, and
DNA 3 μl. The amplification profile was as follows: 94°C
for 4 min, followed by 35 cycles of denaturation at 94°C for30s, annealing at 56°C for 30 s, extension at 72°C for 45 s.
A final extension at 72°C for 4 min was performed.
The set of primers used for the multiplex PCR were as
follows: HPV16 sense 50AAGGGCGTAACCGAAATCGG
T30, antisense 50CATATACCTCACGTCGCAG30; HPV18







CCTG TCCACCGTCCACCG30; HPV45 sense 5GATG
GAAAAGTGCATTACAGG3, antisense 50ACCTCTGTG
CGTTCCAATGT30;HPV52 sense 50TAAGGCTG CAGTG
TGTGCAG30, antisense 50CTAAT AGTTATTTCACTT
AATGGT30.
Samples positive at HPV detection, but negative at
PCR genotyping were re-tested by reverse-line blot
hybridization using the Digene HPV Genotyping RH
(Qiagen) commercial kit, according to the manufac-
turer’s protocol. The kit employed biotynilated primers
(GP5+/GP6+) and the assay targets 18 HPV types [27],
including those classified by the International Agency
for Research on Cancer (IARC) as carcinogenic (Group
1 carcinogen, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59), probably carcinogenic (Group 2A carcinogen,
HPV68), and as possibly carcinogenic to humans (Group
2B carcinogen, HPV26, 53, 66, 73, 82) [28]. PCR biotiny-
lated products (10 μl) were denatured and hybridized with
type-specific oligonucleotide probes immobilized as parallel
lines on nitrocellulose membrane strips. The hybrids were
detected with alkaline phosphatase–streptavidin conjugate
and substrate (5-bromo-4-chloro-3-indolylphosphate and
nitroblue tetrazolium), resulting in a purple precipitate at
positive probe lines. After drying, the strips were analyzed
by visually comparing them with the interpretation grid
supplied in the kit; the presence of a clearly visible line was
considered a positive reaction.
A biotinylated poly (dT) control for conjugate reaction
was applied to each strip to ensure the validity of the test
and proper alignment of the strips on the interpretation
sheet.
HLA-G methylation – pilot analysis
The analysis of the HLA-G methylation was performed as
a pilot analysis on the first set of samples shipped to Italy
from Brazil (N = 172, 76 controls and 96 CIN2/3 cases).
The analysis was performed through bisulfite modification
and pyrosequencing.
Bisulfite modification
Sodium bisulfite modification converts unmethylated
cytosine into uracyl, but leaves the methylated cytosines
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was converted using the EpiTect Bisulfite commercial kit
(Qiagen) according to the manufacturer’s instructions.
Pyrosequencing
Pyrosequencing was used to evaluate HLA-G methylation
status and to quantify the methylation of each individual
CpG investigated. It was performed on a Pyromark Q24
using PyroMark Gold Q24 (Qiagen) reagents. The assay
allowed the quantification of methylation of the seven
CpGs we sited in the HLA-G promoter, using primers
designed with the Pyromark Assay Design software
(Qiagen) according to the HLA-G reference sequence
GenBank J03027.1. Preliminary PCR was performed,
targeting a 441 bp sequence of the HLA-G promoter,
using primers with the following sequences: sense
50GGGAGGTAGGGAGTTTAGTT-TA30, antisense Biotin-
50CCATAACCACCATCCTTAAC30. The primer antisense
is biotinylated to allow binding to sepharose beads during
the subsequent pyrosequencing process. To improve effi-
ciency, three different pairs of sequencing primers that tar-
geted 2, 3 and 2 CpGs, respectively, were employed:
Sequencing primer 1 (2 CpGs, positions 350 and 428)
50GGAGTTTAGTTTAGGGATAG30, Sequencing primer 2
(3 CpGs, positions 494, 512 and 523) 50ATTTAG
GGAGATATTGAGA30, Sequencing primer 3 (2 CpGs,
positions 573 and 598) 50GGGTTTTAGGTTTTATAGG30.
The preliminary PCR reaction was performed in a
total volume of 35 μl containing buffer (KCl) 1X, MgCl2
2 mM, dNTPs 200 μM, 0.5 μM each primer (antisense
biotinylated), Taq polymerase 1.75U and 6 μl converted
DNA with the following cycling profile: 95°C for 1 min
followed by 45 denaturation cycles at 54°C for 1 min,
annealing at 56°C for 1 min, extension at 72°C for
1 min, final extension at 72°C for 10 min. Amplicons
were analyzed by gel electrophoresis on a 2% agarose gel
stained with ethidium bromide and visualized by ultra-
violet trans-illumination. The residual PCR product
(28 μl) was added to 12 μl of dH2O and incubated under
shaking with 37 μl of binding buffer pH 7.6 (10 mM
Tris–HCl; 2 M NaCl; 1 mM EDTA; 0.1% Tween 20) and
3 ml sepharose beads covered with streptavidin. PCR
products were washed with ethanol 70%, denatured with
NaOH 0.2 M and re-washed with Tris-Acetate 10 mM
pH 7.6. Pyrosequencing reaction was performed in 45 μl
of annealing buffer [44.82 μl of 20 mM Tris-Acetate +
5 mM MgAc2 and 0.18 μl of sequencing primer
(0.3 μM)].
Quantitative methylation results were expressed as the
mean of the methylation percentage of all seven CpGs
investigated.
The individual methylation percentage for two CpGs,
one located in a binding site for the transcription factor
specificity protein 1 (Sp1), and the other located in theenhancer region, were also evaluated for their associ-
ation with HPV infection and CIN2/3.
Statistical analyses
Analyses investigating the association between HLA-G
methylation, HPV status, and demographic and lifestyle
factors were restricted to controls, due to the fact that
almost all CIN2/3 cases were HPV-positive. For HLA-G
methylation analyses with sufficiently high frequency,
the t Student test was used, or alternatively the non-
parametric Wilcoxon test. To evaluate whether there
was a difference in the percentage of methylation be-
tween CIN2/3 cases and controls, and to further com-
pare subgroups of the study population (i.e., controls vs.
CIN2 cases, controls vs. CIN3 cases, CIN2 cases vs.
CIN3 cases), the Bonferroni correction for multiple
comparisons was used. Logistic regression models,
adjusted for age, education level, ethnic group and
smoking status, were fitted to evaluate the effect of
HLA-G methylation on the development of cervical can-
cer [crude and adjusted odds ratios (ORs) are reported].
Results
Characteristics of the study population
During the study period 789 women were recruited,
including 510 controls and 279 CIN2/3 cases (150
CIN2, 129 CIN3). CIN2/3 cases and controls had a
comparable mean age (32 years for both), education
level, age at first sexual intercourse (16 years for
cases, 17 years for controls) and number of full-term
pregnancies (Table 1). The ethnic group Brazilian
Mixed showed the highest prevalence of HPV infec-
tion in both CIN2/3 cases and controls. Slight differ-
ences emerged in the distribution of CIN2/3 cases
and controls by ethnic group, sexual factors, and
smoking status. The most represented ethnic group
in CIN2/3 cases was Brazilian Mixed (58.1%), while
in controls it was Euro-Descendent (46.9%). Among
CIN2/3 cases, 74.6% reported a total number of
partners between 2 and 10, while the corresponding
percentage among controls was 53.9%. Current smo-
kers were more common among CIN2/3 cases
(34.4%) than controls (15.9%) (Table 1).
HPV detection and type distribution
We found a HPV prevalence of 19.6% in controls and
94.3% in CIN2/3 cases (Table 2). HPV-positive CIN2/3
cases and controls showed a higher frequency of single
HPV infections (cases 66.2%, controls 65%) than mul-
tiple infections (cases 32.7%, controls 29%). A proportion
of samples could not be typed (cases 1.14%, controls 6%)
by our methods. Among the most frequent genotypes
(HPV16, 18, 31, 33, 35, 45 and 52, IARC Group 1 car-
cinogen [28]) a higher prevalence was observed for
Table 1 Characteristics of the study population
Cases Controls
N % N %
Number 279 510 100 %
Controls (normal cytology) - 510
CIN2 150 53.7 -
CIN3 129 46.3 -
Mean age 32 years 32 years
Range 15-47 15-47
Education level
Elementary school 164 58.8 262 51.4
Middle school 93 33.3 159 31.2
High school 8 2.9 18 3.5
Missing 14 5.0 71 13.9
Ethnic group
Euro-Descendent 90 32.3 239 46.9
Afro-Descendent 7 2.5 24 4.7
Brazilian Mixed* 162 58.1 180 35.3
Asian 1 0.4 1 0.2
Missing 19 6.8 66 12.9
Age at first sexual intercourse 16 years 17 years
Lifetime number of sexual partners
1 42 15.0 156 30.6
2-10 208 74.6 275 53.9
>10 27 9.7 79 15.5
Missing 2 0.7 0 0
Number of full-term pregnancies 2 2
Range 0-18 0-27
Smoking status
Never smoker 130 46.6 277 54.3
Former smoker 51 18.3 148 29.0
Number of cigarettes/day (mean) 7 8
Current smoker 96 34.4 81 15.9
Number of cigarettes/day (mean) 7 8
Missing 2 0.7 4 0.8
*Brazilian Mixed: Mixed ethnicity with Euro-Descendent (mostly), Afro-Descendent, Amerindian and East Asian.
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followed by HPV35, 52, 18 and 45 in CIN2/3 cases, and
HPV18, 35, 52 and 45 in controls (Table 3). A cumula-
tive frequency of 9.3% and 4.9% was detected in CIN2/
34 cases and controls respectively, for HPV types with a
lower prevalence: HPV39, 51, 56, 58 and 59, IARC
Group 1 carcinogen; HPV68, IARC Group 2A carcino-
gen; and HPV26, 53, 66, 73 and 82, IARC Group 2B car-
cinogen [28].Frequency of HPV infection by selected characteristics in
controls
Table 4 reports the frequency of HPV infection by
selected characteristics among controls. HPV infection
was inversely associated with age (p < 0.001), and was
positively associated with lifetime number of sexual part-
ners (p = 0.001), smoking status (p = 0.09) and Brazilian
Mixed ethnic group (p = 0.09). There was no evidence of
association with education level (p = 0.31).









≥45 < 25 2/21 9.52
Education level
Elementary school 57/261 21.84
Middle school 27/159 16.98




Brazilian Mixed* 47/180 26.11
Asian 0/1 0





Never smoker 45/277 16.25
Former smoker 36/148 24.32
Current smoker 19/81 23.46
*Brazilian Mixed: Mixed ethnicity with Euro-Descendent, Afro-Descendent,
Amerindian and East Asian.
Table 2 Frequency of human papillomavirus (HPV)
infection in the study population
Cases Controls
N = 279 N = 510
N % N %
HPV- 16 5.7 410 80.4
HPV+ 263 94.3 100 19.6
Single infections 174 66.2 65 65.0
Multiple infections 86 32.7 29 29.0
Not typed by our methods 3 1.14 6 6.0
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We calculated the mean percentage of methylation of
the seven evaluated CpGs of the HLA-G promoter,
among the 76 controls and 96 CIN2/3 cases included in
the pilot analysis. We did not find lower methylation
levels among CIN2/3 cases as expected, instead they
were slightly higher (Table 5). Demographic and lifestyle
factors, specifically smoking status and ethnicity, were
not associated with mean HLA-G methylation (data not
shown). Moreover, no decrease was found in overall
methylation when HPV-positive and HPV-negative con-
trols were compared (data not shown).
The CpGs located in regulatory sites of the HLA-G pro-
moter, i.e., the binding site for the transcription factor Sp1
(sequence position 573), and the enhancer region (sequence
position 598), were also evaluated individually with the aim
of highlighting any relevant decrease in methylation that
could directly affect gene transcription. The results, strati-
fied for HPV positivity in controls, and for CIN2 and CIN3
in cases, are shown in Table 6. There was no evidence of
any differences in the mean methylation percentage be-
tween CIN2/3 cases and controls for the CpG located inTable 3 Distribution of selected human papillomavirus
(HPV) types in the study population
High-risk HPV types § Cases Controls
N = 279 N = 510
N % N %
HPV16 171 61.3 61.3 38 7.4
HPV18 21 7.5 7.5 9 1.8
HPV31 50 17.9 17.9 16 3.18
HPV33 31 11.1 11.1 12 2.38
HPV35 27 9.7 9.7 8 1.6
HPV45 13 4.7 4.7 6 1.2
HPV52 24 8.6 8.6 7 1.4
Less frequent HPV types* 26 9.3 25 4.9
§ HPV types present in single or multiple infections.
* Includes IARC Group 1 carcinogen types HPV39, 51, 56, 58, 59; Group 2A
carcinogen type HPV 68; and Group 2B carcinogen types HPV26, 53, 59, 66,
73, 82.the binding site for transcription factor Sp1 (crude OR=
1.01, 95% confidence interval [CI]: 0.97,1.06; adjusted OR =
1.01, 95% CI: 0.96,1.07), while the mean methylation per-
centage for the CpG located in the enhancer region was
slightly higher in CIN2/3 cases than in controls (crude OR
= 1.04, 95% CI: 1.00,1.08; adjusted OR = 1.03, 95% CI:
0.99,1.08). These results were confirmed when the analysis
was restricted to HPV-positive controls for both individu-
ally analyzed CpGs (binding site for transcription factorTable 5 Overall mean methylation percentage in the
study population
Cases Controls
N = 96 N = 76
(% Methylation) (% Methylation)
7 CpGs* in HLA-G promoter
mean methylation 75.8 73.7
Range 70 - 83 71 - 83
* CpG sites: position 350, 428, 494, 512, 523, 573, 598 (GenBank: J03027.1).
Table 6 Mean methylation percentage in specific CpG sites
Cases Controls
N = 96 N = 76
CIN2 HPV+ CIN3 HPV + N = 65 HPV + HPV-
N = 31 (% Methylation) N = 42 N = 34
(% Methylation) (% Methylation) (% Methylation)
CpG (Sp1)* mean methylation 83.5 83 82.7 82.4
Range 65-93 70-93 70-91 65 -93
CpG (enhancer)** mean methylation 33.8 36.3 33.8 32.5
Range 21-53 19-69 21-50 20-56
* CpG site position 573; **CpG site position 598 (GenBank: J03027.1).
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0.99, 95% CI: 0.93,1.07; enhancer region: crude OR= 1.03,
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When a threshold of the median percentage of methy-
lation (33%) was applied for the CpG located in the en-
hancer region (Table 7), we obtained a higher proportion
of CIN2/3 cases (61.5%) than controls (47.4%) with
methylation levels over the threshold (crude OR = 1.77,
95% CI: 0.96,3.26; adjusted OR = 1.40, 95% CI: 0.71,2.76).
Discussion
A case–control study was set up in a Brazilian female
population to investigate the relationships between HPV
infection, prevalence of HPV types, methylation status in
the gene promoter of the tolerogenic HLA-G protein
and high-grade cervical lesions.
We explored the occurrence of spontaneous de-
methylation in the HLA-G promoter as a surrogate of re-
expression of the HLA-G protein in HPV-infected cells, as
the HLA-G protein is a recognized inducer of a tolero-
genic effect and tumor escape from immunosurveillance.
By exploring this in a case–control study, our goal was to
try and highlight any association of decreased methylation
with the carcinogenic process. Indeed, according to the
hypothesis of the association with, and role of de-
methylation of the HLA-G protein on oncogenic progres-
sion, our controls were expected to show high HLA-G
methylation, and our CIN2/3 cases were expected to show
low HLA-G methylation. We did not include CIN1 in our
study, as it is less informative given its high rate ofTable 7 Distribution of the study population according to
methylation level of the CpG located in the enhancer
CpG (enhancer)* Cases Controls
N = 96 N = 76
N % N %
Mean methylation <33 % 37 38.5 40 52.6
Mean methylation >33 % 59 61.5 36 47.4
*CpG site position 598 (GenBank: J03027.1).spontaneous regression [29-33]. Similarly, a recent publi-
cation exploring the association between HLA-G expres-
sion and cervical cancer progression also focused on high-
grade lesions only [34].
We did not consider invasive cervical cancer in the
present study, since the occurrence of HLA-G expres-
sion in cervical cancer cells is still controversial in the
scientific literature. Some authors reported variable
HLA-G expression in cervical cancer cells [15,35,36],
others very low or no expression [37,38], suggesting that
if methylation status plays a role in promoting carcino-
genesis, it probably acts in the early phases, rather than
in the advanced phases of the process. For these reasons
we focused our investigation on comparing normal cer-
vical cells with high-grade cervical lesions, in which the
carcinogenic process, if it has started, is more frequently
active.
The HLA-G gene is silenced under physiological con-
ditions independently from proliferative or differentiative
status of normal cells [10,11,39,40]. Therefore the collec-
tion of cervical cells by cytobrush should not have biased
the results of our methylation analyses even if many
dead epithelial cells were present. As expected, we did
find high HLA-G methylation levels in normal cervical
cells, which in this context can be considered appropri-
ate controls.
The percentage of HPV-positive CIN2/3 cases was
very high, as expected. The low proportion of HPV-
negative samples among CIN2/3 cases is consistent with
previous reports of HPV DNA-negative CIN2 and CIN3,
even though an incorrect histological diagnosis was sus-
pected [41-43]. Among controls, HPV positivity was
about 20%, which is in agreement with the mean preva-
lence described in Brazilian populations (10.4%-24.5%)
[44]. Frequency analysis of population characteristics
and HPV infection were conducted in controls only, as
almost all CIN2/3 cases were HPV-positive. This analysis
confirmed the risk factors for HPV infection already
described in the literature, including young age, low edu-
cation level, smoking and a higher lifetime number of
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that showed the highest prevalence of HPV infection,
both in CIN2/3 cases and controls.
The analyses of HPV type distribution in our study
population showed a slight increase in the prevalence of
some types compared to the distribution that has been
previously described in Brazil [24], but were in agree-
ment with the reported prevalence for South America in
a worldwide analysis of HPV type distribution [45].
To our knowledge, this is the first study on HLA-G
methylation and its association with high-grade cervical
lesions. We found a high mean percentage of methyla-
tion in both CIN2/3 cases and controls, without sub-
stantial differences. This is not in line with data reported
for some other cancer types. In ovarian cancer, malig-
nant cells were reported to show higher levels of methy-
lation than normal control cells in some CpG sites, even
though expression of the protein did not properly correl-
ate with the methylation status [17]. In renal cancer
cells, HLA-G expression via partial de-methylation of its
promoter was counted among the strategies used by ma-
lignant cells to escape immune response [46]. Indeed
HLA-G expression is widely documented in renal cancer
cells, while no expression has been reported in normal
renal cells [47-49]. Although HLA-G expression has
been documented in several other cancer sites, i.e. cer-
vical cancer [15,34-37], melanoma [49-51], breast
[49,52-54], colorectal [55-57], gastric [57-60], esophageal
[57,61,62], lung [57,63,64], and other cancers [49], the
implications of HLA-G methylation on the expression of
the protein have not been described.
It has been suggested that even a single CpG dinucleo-
tide could represent a regulatory sequence highly pre-
dictive of the explored outcome [65]. Thus we also
restricted our association analyses to two specific CpGs
that might play a regulatory role, one located in the
binding site of transcription factor Sp1, and one in the
enhancer region. However, no significant differences
were found in methylation between CIN2/3 cases and
controls. Evidence of de-methylation events in CIN2/3
cases with respect to controls, which could suggest a re-
expression of the HLA-G protein in the cells of cervical
high-grade lesions, was not observed. If anything, we
found a slight increase in the overall methylation per-
centage in CIN2/3 cases. This increase was more evident
when the analysis was restricted to the CpG located in
the enhancer region, specifically when a threshold was
set for the methylation level. Although it seems paradox-
ical, this could be explained by the concomitant global
DNA methylation induced by persistent HPV infection
[66]. Recent studies have suggested that HPV can modulate
DNA methylation patterns in order to control cell prolifera-
tion. The oncogenic HPV E7 protein can bind DNA
methyltransferases, stimulating their activity [67]. Indeed,many genes have been shown to be hypermethylated in
neoplastic cervical lesions [68]. We cannot exclude that the
overlap of these hypermethylation events could overshadow
low levels of de-methylation in the HLA-G promoter that
may be present, or that may occur earlier in the car-
cinogenesis process. However the impact of low levels
of de-methylation is unlikely to be functionally
relevant.
Our findings of low HLA-G hypermethylation in
CIN2/3 cases also suggested that alterations in methyla-
tion can be detected in the cervical samples of subjects
with disease despite contamination of the sample by
normal cells. This suggests that the results we obtained
in our pilot analysis on HLA-G methylation are suffi-
ciently suggestive of the absence of detectable de-
methylation events in the HLA-G promoter, without re-
quiring an extension of the analyses to the entire study
population. Realistically, as has been previously reported,
other mechanisms like histone modifications [69], poly-
morphisms [70] or miRNA [71] may modify HLA-G
expression.
We compared population characteristics by HPV sta-
tus and HLA-G promoter methylation, as some charac-
teristics, including ethnicity, have been reported to affect
either one or both of them [72]. If we had found an as-
sociation, it would have been appropriate to evaluate our
results in relation to the demographic and lifestyle char-
acteristics of both cases and controls. However, while we
could confirm known associations of some characteris-
tics with HPV infection, we did not find any association
with HLA-G methylation; we did not observe significant
differences between CIN2/3 cases and controls, nor be-
tween HPV-positive and HPV-negative control women.
Conclusions
This study did not support the hypothesis that spontan-
eous de-methylation events in the HLA-G promoter play
a primary role in the development of precancerous cer-
vical lesions through HLA-G re-expression and conse-
quential promotion of viral and tumor escape from
immunosurveillance. Nor was any association found
between HLA-G methylation and various demographic
and lifestyle factors.
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